Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Current Assets (2016 - 2025)

Anaptysbio's Current Assets history spans 10 years, with the latest figure at $350.2 million for Q4 2025.

  • For Q4 2025, Current Assets fell 18.9% year-over-year to $350.2 million; the TTM value through Dec 2025 reached $350.2 million, down 18.9%, while the annual FY2025 figure was $350.2 million, 18.9% down from the prior year.
  • Current Assets reached $350.2 million in Q4 2025 per ANAB's latest filing, up from $330.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $553.9 million in Q4 2021 to a low of $291.9 million in Q2 2025.
  • Average Current Assets over 5 years is $412.8 million, with a median of $417.4 million recorded in 2023.
  • Peak YoY movement for Current Assets: surged 39.67% in 2021, then fell 26.31% in 2025.
  • A 5-year view of Current Assets shows it stood at $553.9 million in 2021, then fell by 19.26% to $447.2 million in 2022, then dropped by 9.03% to $406.8 million in 2023, then rose by 6.16% to $431.9 million in 2024, then fell by 18.9% to $350.2 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Current Assets are $350.2 million (Q4 2025), $330.6 million (Q3 2025), and $291.9 million (Q2 2025).